Perspective Therapeutics, Inc.
CATX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $255 | $243 | $154 | $225 |
| - Cash | $27 | $29 | $44 | $62 |
| + Debt | $3 | $4 | $4 | $4 |
| Enterprise Value | $231 | $218 | $114 | $168 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -27.9% | -15.2% | – | – |
| Gross Profit | -$1 | -$0 | -$0 | $0 |
| % Margin | -270.8% | -152.8% | -114% | – |
| EBITDA | -$25 | -$21 | -$17 | -$42 |
| % Margin | -12,023.4% | -7,292.1% | -5,063.5% | – |
| Net Income | -$26 | -$21 | -$18 | -$40 |
| % Margin | -12,425.4% | -7,408.6% | -5,314.9% | – |
| EPS Diluted | -0.35 | -0.3 | -0.25 | -0.57 |
| % Growth | -16.7% | -20% | 56.1% | – |
| Operating Cash Flow | -$16 | -$14 | -$22 | -$27 |
| Capital Expenditures | -$2 | -$5 | -$5 | -$15 |
| Free Cash Flow | -$18 | -$19 | -$26 | -$41 |